Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-MFBG PET Imaging in Neural Crest and Neuroendocrine Tumors
NCT04258592Phase 1Terminated
- Sponsor
- UZ Leuven
- Start
- Feb 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of florbenguane F-18 in Neural crest-derived tumor (NCDT) and Neuroendocrine Neoplasm (NEN), sponsored by UZ Leuven. Primary endpoint: Confirmation of 18F-MFBG as a hNET imaging agent in patients with neural crest and neuroendocrine tumors at 20 months. Started Feb 2020; status: terminated.
02
Drugs
florbenguane F-18
03
Conditions
Neural crest-derived tumor (NCDT)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04258592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258592.